Denemek ALTIN - Özgür
TCS, Infy hop onto Adobe's platform to sell AI services
Mint Chennai
|March 25, 2025
Indian IT firms leverage the software maker's agentic AI to sell a full suite of automation tools
India's top software services firms, which have lagged Accenture PLC in selling generative artificial intelligence (AI)-based services to clients, are piggybacking on software maker Adobe Inc.'s platform to win more clients incorporating AI into their businesses.
Tata Consultancy Services Ltd and Infosys Ltd, the two largest technology outsourcing companies in India, are leveraging Adobe's agentic AI push to sell a full suite of automation tools, according to executives and analysts Mint spoke with. At stake is TCS and Infosys' ability to report higher revenue earned from core generative AI deals—which has been a rarity for Indian information technology (IT) services providers.
Adobe, whose key offering in its 43-year history has been its creative software platforms such as Photoshop, After Effects, InDesign and Premiere Pro, earned $21.51 billion in annual revenue last fiscal and has guided for $23.55 billion at a 9.5% annual growth in FY25. While not counted among the Big Tech companies of the US, Adobe ranks among the world's top 100 most valuable firms, with a market capitalization of $169 billion at the time of writing.
Bu hikaye Mint Chennai dergisinin March 25, 2025 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
Mint Chennai'den DAHA FAZLA HİKAYE
Mint Chennai
Lenskart wants artificial intelligence to test your eyes
It expects AI-enabled eye testing to become the default foundational layer of eyecare delivery
3 mins
January 13, 2026
Mint Chennai
More companies to take a hit as labour codes debut
Reworked gratuity and leave encashments spell additional expenses for India Inc
2 mins
January 13, 2026
Mint Chennai
HC lifts ban on Zydus cancer biosimilar till patent expiry
In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.
2 mins
January 13, 2026
Mint Chennai
Trump’s investigation of Powell is also a warning to the next Fed chair
The criminal investigation into Federal Reserve Chair Jerome Powell isn’t ultimately about the Fed’s headquarters, or Powell, or even interest rates.
3 mins
January 13, 2026
Mint Chennai
States flag Almont-Kid syrup as tests find contaminants
Syrup found ‘Not of Standard Quality’ with contaminants like toxic ethylene glycol
1 mins
January 13, 2026
Mint Chennai
India at 100: Our choices today will define the next two decades
India's 2047 ambition is not guaranteed but achievable if we address all the potential pitfalls along our development path
4 mins
January 13, 2026
Mint Chennai
Now, inheritance works without probate—but why it still matters
Heirs can now act on a valid will without court cases, easing delays and unlocking assets in undisputed cases
6 mins
January 13, 2026
Mint Chennai
Why VCs have a new deep-tech playbook
where fundraising starts to drag,\" said Chand.
1 min
January 13, 2026
Mint Chennai
TCS, HCLTech deliver Q3 revenue surprise
clearer.
2 mins
January 13, 2026
Mint Chennai
US productivity is rising and it risks warping monetary policy
America's neutral rate ought to be going up but will the Fed listen?
3 mins
January 13, 2026
Listen
Translate
Change font size
